Invex Therapeutics (IXC) Stock Price, News & Analysis

Company Overview

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $5.64 million
• P/E Ratio: N/A
• Dividend Yield: 230.00%
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:IXC
• CIK: N/A
• Web: www.invextherapeutics.com
• Phone: 61 8 6382 0137
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): A($0.02)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$1.64 million
• Net Margins: -135.43%
• Pretax Margin: N/A
• Return on Equity: -29.89%
• Return on Assets: -9.22%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.18
• Quick Ratio: 29.36

Sales & Book Value

• Annual Sales: $1.21 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: A$0.08 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 75,150,000
• Free Float: N/A
• Market Cap: $5.64 million
• Optionable: Not Optionable
• Beta: 0.47